Feasibility and outcomes of bronchial artery embolization in patients with non-massive hemoptysis
Autor: | Jeong Ho Kim, So Hyun Park, Jung Han Hwang, Suyoung Park, Ki Hyun Lee |
---|---|
Rok vydání: | 2021 |
Předmět: |
Adult
Male Hemoptysis medicine.medical_specialty Tuberculosis medicine.medical_treatment Bronchial Arteries Catheterization Cohort Studies Diseases of the respiratory system Embolization Quality of life Bronchoscopy medicine.artery Humans Medicine In patient Survival rate Aged Retrospective Studies Bronchial artery RC705-779 medicine.diagnostic_test Medical treatment business.industry Research Middle Aged medicine.disease Embolization Therapeutic Gelatin Sponge Absorbable Contrast-enhanced CT Surgery Treatment Outcome Feasibility Studies Female business Follow-Up Studies |
Zdroj: | Respiratory Research Respiratory Research, Vol 22, Iss 1, Pp 1-9 (2021) |
ISSN: | 1465-993X |
Popis: | Purpose To evaluate the safety, efficacy, and long-term outcome of bronchial artery embolization (BAE) in the treatment of non-massive hemoptysis and the prognostic factors associated with recurrent bleeding. Materials and methods From March 2005 to September 2014, BAE was performed in 233 patients with non-massive hemoptysis. All patients had a history of persistent or recurrent hemoptysis despite conservative medical treatment. We assessed the technical and clinical success, recurrence, prognostic factors related to recurrent bleeding, recurrence-free survival rate, additional treatment, and major complications in all the patients. Results Technical success was achieved in 224 patients (96.1%), and clinical success was obtained in 219 (94.0%) of the 233 patients. In addition, 64 patients (27.5%) presented hemoptysis recurrence with median time of 197 days after embolization. Tuberculosis sequelae and presence of aberrant bronchial artery or non-bronchial systemic collaterals were significantly related to recurrent bleeding (p p p = 0.013). Presence of aberrant bronchial artery or non-bronchial systemic collaterals showed a statistically significant correlation with recurrence-free survival rate (p = 0.021). No patients had major complications during follow-up. Conclusions BAE is a safe and effective treatment to manage non-massive hemoptysis. The procedure may offer a better long-term control of recurrent hemoptysis and quality of life than conservative therapy alone. |
Databáze: | OpenAIRE |
Externí odkaz: |